A newly established megakaryoblastic/erythroid cell line that differentiates to red cells in the presence of erythropoietin and produces platelet-like particles.
In August, 1992, we established a leukemic cell line (NS-Meg) from a patient in megakaryoblastic transformation of Philadelphia chromosome-positive chronic myeloid leukemia. The NS-Meg cells were positive for alpha-naphthyl acetate esterase and periodic acid-Schiff (PAS) staining and for surface CD4, CD7, CD13, CD34, CD41a, and glycophorin A antigens. Ultrastructurally, the cells had alpha-granules, demarcation membranes, and platelet peroxidase activity. The NS-Meg cells spontaneously produced platelet-like particles which contained alpha-granules, mitochondria and dense bodies, strongly suggesting platelet production. Erythropoietin (Epo), granulocyte/macrophage colony stimulating factor(GM-CSF), and interleukin 3 (IL-3) promoted the growth of NS-Meg cells. Phorbol-12-myristate-13-acetate increased the expression of both CD41a and CD61 antigens. Ten-day exposure to Epo induced mature erythroblasts and red cells. These benzidine-positive cells were positive for hemoglobin F staining. Untreated NS-Meg cells expressed mRNA for the Epo receptor (EpoR), for GATA-1, and for alpha 1, alpha 2 and gamma globin genes. These results indicate that NS-Meg cells undergo terminal differentiation of both megakaryocytic and erythroid lineages. This cell line should be a very useful tool for the investigation of both megakaryocytic and erythroid maturation.
Tsuyuoka
R
R
Department of Medicine, Kyoto University Faculty of Medicine, Japan.
Takahashi
T
T
Suzuki
A
A
Sasaki
Y
Y
Nakamura
K
K
Fukumoto
M
M
Ohmori
K
K
Ohno
Y
Y
Nakao
K
K
D000328:Adult; D001483:Base Sequence; D001792:Blood Platelets / Q000166:cytology; D002454:Cell Differentiation; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D016207:Cytokines / Q000494:pharmacology; D017931:DNA Primers / Q000737:chemistry; D004268:DNA-Binding Proteins / Q000235:genetics; D015672:Erythroid Precursor Cells / Q000166:cytology*; D050981:Erythroid-Specific DNA-Binding Factors; D004920:Erythropoiesis; D004921:Erythropoietin / Q000494:pharmacology; D005260:Female; D050982:GATA1 Transcription Factor; D015870:Gene Expression; D005914:Globins / Q000235:genetics; D006410:Hematopoiesis; D006801:Humans; D016130:Immunophenotyping; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive; D008533:Megakaryocytes / Q000166:cytology*; D008854:Microscopy, Electron; D008969:Molecular Sequence Data; D012333:RNA, Messenger / Q000235:genetics; D017467:Receptors, Erythropoietin / Q000235:genetics; D014157:Transcription Factors / Q000235:genetics; D014407:Tumor Cells, Cultured
D016207:Cytokines; D017931:DNA Primers; D004268:DNA-Binding Proteins; D050981:Erythroid-Specific DNA-Binding Factors; D050982:GATA1 Transcription Factor; C494688:GATA1 protein, human; D012333:RNA, Messenger; D017467:Receptors, Erythropoietin; D014157:Transcription Factors; D004921:Erythropoietin; D005914:Globins